Safety Evaluation of Contezolid (MRX-I) Versus Linezolid in Sprague-Dawley Rats
Abstract Background & Objectives Contezolid (MRX-I) is a novel ortho-fluorophenyl dihydropyridone developed by MicuRx Pharmaceuticals, Inc. It has been approved for the treatment of drug-resistant Gram-positive bacterial infections with relatively lower toxicity than other oxazolidinones such as lin...
保存先:
| 主要な著者: | , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Adis, Springer Healthcare
2025-05-01
|
| シリーズ: | Drugs in R&D |
| オンライン･アクセス: | https://doi.org/10.1007/s40268-025-00504-x |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|